title: Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass.
abstract: OBJECTIVE
  To evaluate the possible protective effects of fenoldopam on renal function in patients undergoing cardiopulmonary bypass.
  
  
  METHODS
  Prospective, randomized trial.
  
  
  METHODS
  University teaching hospital.
  
  
  METHODS
  One hundred sixty consecutive patients with serum creatinine >1.5 mg/dL who underwent uncomplicated moderate hypothermic cardiopulmonary bypass for cardiac surgery.
  
  
  METHODS
  A random group of 80 patients was managed conventionally (group A), whereas another random group of 80 patients received continuous intravenous administration of low-dose fenoldopam (0.1-0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B).
  
  
  RESULTS
  An improvement of postoperative renal parameters were observed only in group B: preoperative serum creatinine 1.82 +/- 0.2 versus 1.43 +/- 0.73 postoperatively (p < 0.001), preoperative creatinine clearance 51.34 +/- 22.26 versus 67.14 +/- 18.55 postoperatively (p < 0.001).
  
  
  CONCLUSIONS
  In this study, fenoldopam was an effective agent in the prevention of renal dysfunction after cardiopulmonary bypass.
authors.affiliation: Department of Cardiac Surgery, University of East Piedmont, School of Medicine, Novara, Italy. philippeprimo.caimmi@tin.it
authors.forename: Philippe-Primo
authors.initials: PP
authors.lastname: Caimmi
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Pagani
authors.forename: Ezio
authors.initials: E
authors.lastname: Micalizzi
authors.forename: Cosimo
authors.initials: C
authors.lastname: Fiume
authors.forename: Simona
authors.initials: S
authors.lastname: Guani
authors.forename: Massimo
authors.initials: M
authors.lastname: Bernardi
authors.forename: Fillipo
authors.initials: F
authors.lastname: Parodi
authors.forename: Gualtiero
authors.initials: G
authors.lastname: Cordero
authors.forename: Maura
authors.initials: M
authors.lastname: Fregonara
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Kapetanakis
authors.forename: Massinniano
authors.initials: M
authors.lastname: Panella
authors.forename: Carlo
authors.initials: C
authors.lastname: Degasperis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002315:Cardiopulmonary Bypass; D003404:Creatinine / Q000097:blood; D004232:Diuretics / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D018818:Fenoldopam / Q000008:administration & dosage / Q000627:therapeutic use*; D005431:Florida; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology*; D007674:Kidney Diseases / Q000517:prevention & control*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011446:Prospective Studies; D016896:Treatment Outcome; D014554:Urination / Q000187:drug effects / Q000502:physiology
chemical_list: D015415:Biomarkers; D004232:Diuretics; D018491:Dopamine Agonists; D005665:Furosemide; D003404:Creatinine; D018818:Fenoldopam; D011188:Potassium